Finnegan tees up valuable patents for Principia Biopharma, leading to major acquisition deal

Completed successful patent prosecution for Principia. By entrusting Finnegan to obtain strong patents for their Phase 1 candidate, Principia was able to secure an exclusive, worldwide license agreement with Sanofi to develop and commercialize PRN2246, with the potential for $765 million in milestone payments. Finnegan also successfully prosecuted patents directed to compound PRN1008, a BTK inhibitor that Principia is investigating for autoimmune and inflammatory diseases. Principia’s impressive pipeline of drug candidates, covered by a patent portfolio prosecuted by Finnegan, led to an IPO in which Principia raised over $100 million. Sanofi agreed to pay $3.7 billion to acquire Principia.